• PIN74 LEAST COSTLY VACCINATION STRATEGY (WITH OR WITHOUT SCREENING FOR ANTOBODIES) FOR HEPATITIS A, HEPATITIS B, VARICELLA, MEASLES AND TETANUS IN CATALONIA, SPAIN

    Oct 1, 2009, 00:00

  • PUK8 THE COST-EFFECTIVENESS OF PHOSPHATE BINDERS FOR THE TREATMENT OF HYPERPHOSPHATEMIA IN CHRONIC KIDNEY DISEASE (CKD)

    Oct 1, 2009, 00:00

  • PCV54 EXAMINING THE COST IMPACTS OF RECONFIGURING TIA CARE IN SPAIN

    Oct 1, 2009, 00:00

  • PIH26 TREATMENT DURATION AND PRESCRIPTION REFILL RATE FOR VAGINAL ESTROGEN THERAPY IN MEDICAID ENROLLED WOMEN WITH ATROPHIC VAGINITIS

    Oct 1, 2009, 00:00

  • DB1 USING POPULATION-BASED ESTIMATES FOR DISEASE MODELING- POTENTIAL BIAS COMPARED TO USING DISEASE-SPECIFIC DEATH AND COMPLICATION RISK ESTIMATES

    Oct 1, 2009, 00:00

  • MO11 WHEN DOES VALUE OF INFORMATION ANALYSIS ADD VALUE?

    Oct 1, 2009, 00:00

  • PG116 RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH OPIOIDINDUCED CONSTIPATION (OIC) IN CANCER PATIENTS IN SWEDEN

    Oct 1, 2009, 00:00

  • PCV166 ADENOSINE-STRESS CARDIAC MAGNETIC RESONANCE IMAGING IN SUSPECTED CORONARY ARTERY DISEASE- A NET COST ANALYSIS REIMBURSEMENT IMPLICATIONS

    Oct 1, 2009, 00:00

  • PCN92 COST-EFECTIVENESS ANALYSIS OF DOCETAXEL VS DOCETAXEL+TRASTUZUMAB AS FIRST LINE THERAPY IN THE TREATMENT OF PATIENTS WITH METATSTASTIC BREAST CANCER HER2/NEU+

    Oct 1, 2009, 00:00

  • PDB21 WHO ARE THEY FOOLING?- COST OF DISEASE OR COMPLICATIONS CAN SIGNIFICANTLY BIAS ESTIMATES UNLESS CONTROL (NON-DISEASED) COSTS ARE NOT ALSO ACCOUNTED FOR IN THE ANALYSIS

    Oct 1, 2009, 00:00

  • PMC28 EXPERT SURVEY FOR INCREMENTAL COST-EFFECTIVENESS RATIO (ICER) THRESHOLD RANGE IN KOREA- DISCRETE CHOICE EXPERIMENTS

    Oct 1, 2009, 00:00

  • PDB73 ANALYSIS OF FACTORS INFLUENCING DECISION MAKING ON TYPE 2 DIABETES DRUGS IN 5 HTA-AGENCIES

    Oct 1, 2009, 00:00

  • PIH22 HEALTH ECONOMIC EVALUATION OF A NEW VACCINE FOR THE PREVENTION OF HERPES ZOSTER AND POST-HERPETIC NEURALGIA IN ADULTS A GERMAN ANALYSIS

    Oct 1, 2009, 00:00

  • PDB9 ECONOMIC EVALUATION OF LONG TERM SOMATOSTATIN ANALOGS IN THE TREATMENT OF ACROMEGALY IN MEXICO- MONOTHERAPY VS SEQUENTIAL THERAPY

    Oct 1, 2009, 00:00

  • PSS17 A HEALTH ECONOMIC EVALUATION OF ELIMINATING NONCOMPLIANCE WITH ORAL TREATMENT OF SKIN AND SOFT TISSUE INFECTIONS IN DOGS IN GERMANY

    Oct 1, 2009, 00:00

  • PCV13 COST-EFFECTIVENESS ANALYSIS OF B-TYPE NATRIURETIC PEPTIDE COMPARED TO CLINICAL JUDGMENT IN PATIENTS PRESENTING TO ACUTE CARE SETTINGS WITH DYSPNEA IN UNIFIED HEALTH SYSTEM

    Oct 1, 2009, 00:00

  • PSY2 EFFECT OF WRITTEN EMOTIONAL DISCLOSURE INTERVENTIONS IN PERSONS WITH PSORIASIS UNDERGOING NARROW BAND ULTRAVIOLET B PHOTOTHERAPY

    Oct 1, 2009, 00:00

  • PHP28 PHARMACEUTICAL CARE IN THE EYES OF THE PATIENT

    Oct 1, 2009, 00:00

  • PMS9 COST-MINIMIZATION ANALYSIS OF VISCOSUPPLEMENTATION TREATMENT OSTEOARTHRITIS OF KNEE IN BRAZILS PRIVATE SECTOR

    Oct 1, 2009, 00:00

  • PMS17 BUDGET IMPACT ANALYSIS OF REIMBURSEMENT OF ARAVA (LEFLUNOMIDE) IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN POLAND

    Oct 1, 2009, 00:00

  • PCN123 LONG-TERM COST-EFFECTIVENESS OF ANASTROZOLE VERSUS TAMOXIFEN-AN UPDATED ANALYSIS BASED UPON THE 100 MONTH FOLLOW UP OF THE ANASTROZOLE OR TAMOXIFEN ALONE OR IN COMBINATION (ATAC) TRIAL

    Oct 1, 2009, 00:00

  • PDB2 COSTS OF DISEASE COMPLICATIONS RELATED TO DM2 IN MEXICO- A SYSTEMATIC REVIEW

    Oct 1, 2009, 00:00

  • CS7 COST-EFFECTIVENESS AND BUDGET IMPACT OF INTRODUCING ROSUVASTATIN INTO THE BRAZILIAN NATIONAL DRUG FORMULARY

    Oct 1, 2009, 00:00

  • PRS5 COST-EFFECTIVENESS OF PHARMACOLOGICAL INTERVENTIONS FOR SMOKING CESSATION- CURRENT EVIDENCE AND POLICY IMPLICATIONS

    Oct 1, 2009, 00:00

  • CO4 MICRO-COSTING VS GROSS-COSTING IN THE ESTIMATION OF COSTS FOR THE PHARMACOECONOMIC EVALUATION OF GLAUCOMA IN KOREA

    Oct 1, 2009, 00:00

  • PSY48 INSOMNIA AMONGST PATIENTS WITH CHRONIC PAIN AND INFLUENCE OF ADJUSTMENT OF PAIN MEDICATION IN GERMANY

    Oct 1, 2009, 00:00

  • PSS23 COST-EFFECTIVENESS ANALYSIS OF IMIQUIMOD VERSUS NO TREATMENT IN ACTINIC KERATOSES

    Oct 1, 2009, 00:00

  • PCN148 ADDRESSING DECISIONS ABOUT CLINICAL GUIDANCE AND ITS ACTIVE IMPLEMENTATION- SEQUENTIAL OR INTEGRAL ANALYSIS? AN APPLICATION IN METASTATIC HORMONE-REFRACTORY PROSTATE CANCER

    Oct 1, 2009, 00:00

  • PHP24 ANTIPSYCHOTICS CONSUMPTION IN THE REPUBLIC OF CROATIA IN 2005, 2006 AND 2007

    Oct 1, 2009, 00:00

  • PSS40 CAN WE RELY ON SCORES FROM THE DERMATOLOGY LIFE QUALITY INDEX?

    Oct 1, 2009, 00:00

  • PCN147 FIELD TESTING OF A MULTICRITERIA DECISION ANALYSES (MCDA) FRAMEWORK FOR COVERAGE OF A DIAGNOSTIC TEST FOR CERVICAL CANCER IN SOUTH AFRICA

    Oct 1, 2009, 00:00

  • PMC55 AGREEMENT BETWEEN PATIENT AND PROXY ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE BEFORE INTENSIVE CARE UNIT ADMISSION

    Oct 1, 2009, 00:00

  • PMH20 IMPACT OF DISEASE SEVERITY ON DURATION OF HOSPITALIZATION IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH OLANZAPINE OR HALOPERIDOL IN GERMANY- POST-HOC ANALYSIS OF DATA COLLECTED IN THE GEO STUDY

    Oct 1, 2009, 00:00

  • PMS54 COST-EFFECTIVENESS OF TOCILIZUMAB COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF MODERATE/SEVERE RHEUMATOID ARTHRITIS (RA) IN ITALY

    Oct 1, 2009, 00:00

  • PCV8 COST OF ILLNESS IN PATIENTS WITH PULMONARY EMBOLISM AFTER ELECTIVE TOTAL HIP REPLACEMENT

    Oct 1, 2009, 00:00

  • PSS27 A COST-UTILITY ANALYSIS OF ETANERCEPT FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS IN ITALY

    Oct 1, 2009, 00:00

  • HP2 HEALTH TECHNOLOGY ASSESSMENT IN LATIN-AMERICA AND THE CARIBBEAN, FACILITATORS AND BARRIERS FOR INTERNATIONAL COLLABORATION- A SURVEY

    Oct 1, 2009, 00:00

  • PCV52 ECONFIGURING TIA CARE PATHWAYS IN HUNGARY- AVOIDING RECURRENT STROKE

    Oct 1, 2009, 00:00

  • PMS28 COSTS AVOIDED BY DIAGNOSING FIBROMYALGIA

    Oct 1, 2009, 00:00

  • PND9 COST-EFFECTIVENESS AND BUDGET IMPACT MODELLING OF LACOSAMIDE IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN FINLAND

    Oct 1, 2009, 00:00

  • PMH64 THE POSTTRAUMATIC STRESS AMONG AMBULANCE PERSONNEL IN HUNGARY

    Oct 1, 2009, 00:00

  • PSS15 COSTS OF GLAUCOMA IN DENMARK

    Oct 1, 2009, 00:00

  • PDB13 MEDICATION PATTERN AND RISK OF STROKE AMONG TYPE II DIABETES MELLITUS IN TAIWAN-A POPULATION-BASED STUDY

    Oct 1, 2009, 00:00

  • PIH5 EXAMINATION OF GAIT DURING THE TRIMESTERS OF PREGNANCY

    Oct 1, 2009, 00:00

  • PMC23 UNDERESTIMATION OF UNCERTAINTY IN COST-EFFECTIVENESS ACCEPTABILITY CURVES AND EXPECTED VALUE OF INFORMATION ANALYSES

    Oct 1, 2009, 00:00

  • PIN12 EVALUACIN DE LA VACUNA DE NEUMOCOCO EN COLOMBIA

    Oct 1, 2009, 00:00

  • PCV9 AVALIAO PARA PACIENTES AMBULATORIAIS MEDICADOS COM ANTI-HIPERTENSIVOS

    Oct 1, 2009, 00:00

  • PMS35 COST-EFFECTIVENESS OF BIOLOGIC THERAPEUTIC SEQUENCES FOR RHEUMATOID ARTHRITIS IN THE UK

    Oct 1, 2009, 00:00

  • PMS75 OAKHQOL, A DISEASE-SPECIFIC HEALTH RELATED QUALITY OF LIFE QUESTIONNAIRE FOR OSTEOARTHRITIS OF THE LOWER LIMB. VALIDITY AND RESPONSIVENESS

    Oct 1, 2009, 00:00

  • VA6 INTEGRATED DYNAMIC TRANSMISSION/COST-EFFECTIVENESS MODEL FOR INFLUENZA A AND B PART I- DEVELOPMENT OF AN INTEGRATED MODEL

    Oct 1, 2009, 00:00

  • PDB25 A PATIENT-LEVEL SIMULATION MODEL FOR ECONOMIC EVALUATION OF CINACALCET IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM (SHPT) IN ITALY

    Oct 1, 2009, 00:00

  • PIH6 RESOURCE USE AND DIRECT MEDICAL COSTS ASSOCIATED TO PNEUMOCOCCAL DISEASE-RELATED HOSPITALIZATIONS ON BRAZILIAN PUBLIC HEALTH CARE SYSTEM

    Oct 1, 2009, 00:00

  • PCN37 EXPECTED ECONOMIC BURDEN OF TREATING ADVANCED SOFT TISSUE SARCOMAS WITH TRABECTEDIN IN RUSSIA

    Oct 1, 2009, 00:00

  • PSY43 MAPPING THE ROLAND MORRIS DISABILITY QUESTIONNAIRE FOR BACK PAIN INTO UTILITY INDEX

    Oct 1, 2009, 00:00

  • PCV77 HEALTH CARE COSTS AND RESOURCE UTILIZATION FOR ACUTE CORONARY SYNDROME IN PATIENTS WITH AND WITHOUT DIABETES MELLITUS

    Oct 1, 2009, 00:00

  • CO1 GANHOS ASSOCIADOS A EXAMES CLFICO PARA MULHERES ACIMA DOS 40 ANOS

    Oct 1, 2009, 00:00

  • PMS12 USTEKINUMAB RESULTS- IN RAPID, SUSTAINED AND CLINICALLY MEANINGFUL IMPROVEMENTS IN PHYSICAL DISABILITY AND QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS- RESULTS- FROM A RANDOMIZED AND PLACEBO-CONTROLLED PHASE II TRIAL

    Oct 1, 2009, 00:00

  • PHP93 POTENTIAL COST-SAVINGS USING IMPLANTABLE LOOP RECORDERS (ILRS) FOR UNEXPLAINED SYNCOPE DIAGNOSTICS- THE CASE FOR THE NETHERLANDS

    Oct 1, 2009, 00:00

  • PMS85 EQ-5D VISUAL ANALOGUE SCALE (VAS) AND UTILITY INDEX VALUES IN FRENCH WOMEN WITH A DIAGNOSIS OF POST-MENOPAUSAL OSTEOPOROSIS

    Oct 1, 2009, 00:00

  • PCN110 COST-MINIMIZATION ANALYSIS OF XELOX VERSUS FOLFOX +/- BEVACIZUMAB FOR TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN SAUDI ARABIAN HOSPITAL SETTING

    Oct 1, 2009, 00:00

  • PHP100 PHARMACY STUDY OF NATURAL HEALTH PRODUCT ADVERSE REACTIONS (SONAR)- ACTIVE SURVEILLANCE INCREASES AR REPORTING AND REVEALS TWO NEW INTERACTIONS

    Oct 1, 2009, 00:00

  • PCV15 COMBINED OPTIMAL LIPID VALUE GOAL ATTAINMENT AFTER TREATMENT INITIATION WITH SIMVASTATIN PLUS NIACIN EXTENDED-RELEASE COMBINATION THERAPY VERSUS EZETIMIBE PLUS SIMVASTATIN COMBINATION THERAPY IN A MANAGED CARE PATIENT POPULATION WITH ...

    Oct 1, 2009, 00:00

  • PMS73 CONTENT VALIDITY OF THE FIBROMYALGIA SYNDROME BURDEN ASSESSMENT (FMBA)

    Oct 1, 2009, 00:00

  • MH4 COMORBID DEPRESSION IN PATIENTS DIAGNOSED WITH TYPE 2 DIABETES MELLITUS (T2DM)- EFFECTS ON QUALITY OF LIFE AND RESOURCE USE

    Oct 1, 2009, 00:00

  • PCN70 COST EFFECTIVENESS ANALYSIS OF SUNITINIB, BEVACIZUMAB + INTERFERON-ALFA AND TEMSIROLIMUS AS FIRST-LINE THERAPY OF METASTATIC RENAL CELL CARCINOMA IN SWEDEN

    Oct 1, 2009, 00:00

  • PCV3 HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND RISK FOR MAJOR CARDIOVASCULAR EVENTS IN MEN AND WOMEN

    Oct 1, 2009, 00:00

  • PCV139 PREFERENCE AND WILLINGNESS-TO-PAY STUDY TO ASSESS THE VALUE OF AN ANTICOAGULATION THERAPY MODELLED ON DABIGATRAN ETEXILATE USING DISCRETE CHOICE ANALYSIS- A UK PILOT STUDY OF ATRIAL FIBRILLATION PATIENTS RECEIVING WARFARIN

    Oct 1, 2009, 00:00

  • PMS5 COST-EFFECTIVENESS OF THE USE OF ETANERCEPT VS ANTI-TNF MONOCLONAL ANTIBODIES IN PATIENTS WITH RHEUMATOID ARTHRITIS IN MEXICO

    Oct 1, 2009, 00:00

  • PCN129 FACTORS AFFECTING ADMINISTRATION REGIMES AND COSTS ASSOCIATED WITH EIGHT FIRST-LINE CHEMOTHERAPEUTIC DRUGS IN SEVEN COMBINATIONS, IN THE TREATMENT OF MNSCLC

    Oct 1, 2009, 00:00

  • PMH8 CLINICAL EFFICACY AND SAFETY OF DULOXETINE IN COMPARISON WITH PLACEBO IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN POLAND

    Oct 1, 2009, 00:00

  • PMC3 ESTADO DEL ARTE DE LA EVALUACITICA DE LA LITERATURA

    Oct 1, 2009, 00:00

  • PCV42 CONFORMATION OF BLEEDING QUANTITY MEASURED AFTER HEART OPERATIONS ACCORDING TO METEOROLOGICAL AND ASTRONOMICAL FACTORS

    Oct 1, 2009, 00:00

  • PIN67 QUALITY OF LIFE AND HEALTH CARE UTILIZATION BURDEN OF HCV-INFECTED PATIENTS IN EUROPE

    Oct 1, 2009, 00:00

  • CS2 COST-EFFECTIVENESS OF SMOKING CESSATION INTERVENTIONS IN SEVEN LATIN AMERICAN COUNTRIES

    Oct 1, 2009, 00:00

  • PMS66 GRAND- THE GERMAN RETROSPECTIVE COHORT ANALYSIS ON NON-ADHERENCE AND ASSOCIATED RISK OF FRACTURES IN OSTEOPOROSIS PATIENTS TREATED WITH ORAL BISPHOSPHONATES

    Oct 1, 2009, 00:00

  • PHP56 THE ROLE OF PHARMACOECONOMICS IN DRUG REIMBURSEMENT DECISION-MAKING IN THE NETHERLANDS

    Oct 1, 2009, 00:00

  • PSY33 A COST-UTILITY ANALYSIS OF IDET COMPARED WITH SPINAL FUSION

    Oct 1, 2009, 00:00

  • PMS90 FIBROMYALGIA- RUSSIAN RHEUMATOLOGISTS DISEASE MANAGEMENT

    Oct 1, 2009, 00:00

  • PCN44 TREATMENT COSTS OF GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN

    Oct 1, 2009, 00:00

  • PHP6 ACUT CARE HOSPITAL BED OCCUPANCY RATE IN HUNGARY BETWEEN 2000 AND 2008

    Oct 1, 2009, 00:00

  • PCV19 EFFECT OF CALCIUM CHANNEL BLOCKERS ON CARDIOVASCULAR DISEASE PREVENTION

    Oct 1, 2009, 00:00

  • PCN42 ECONOMIC EVALUATION OF THE USE OF HAEMOSTATIC SEALANT PATCH FOR PULMONARY LOBECTOMY PROCEDURE

    Oct 1, 2009, 00:00

  • PCN140 IMPACT OF TUMOR RESPONSE ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH VELCADE/MELPHALAN/PREDNISONE (V-MP)- RESULTS FROM THE VISTA TRIAL

    Oct 1, 2009, 00:00

  • PMH65 ASSOCIATION BETWEEN EARLY ANTIDEPRESSANT RESPONSE AND QUALITY OF LIFE AMONG PATIENT WITH DEPRESSION- RESULTS FROM A 1-YEAR FOLLOW-UP LARGE EPIDEMIOLOGICAL STUDY

    Oct 1, 2009, 00:00

  • ISPOR Twelfth Annual European Congress Author Index

    Oct 1, 2009, 00:00

  • CO4 AUTOMATED PHONE CALLS IMPROVED ADHERENCE TO INHALED CORTICOSTEROIDS

    Oct 1, 2009, 00:00

  • MH3 ANTIPSYCHOTIC USE AND DIABETES- A NESTED CASE-CONTROL ANALYSIS IN A COHORT OF NEW ANTIPSYCHOTIC USERS

    Oct 1, 2009, 00:00

  • PRS22 COST-EFFECTIVENESS ANALYSIS OF TIOTROPIUM IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS IN SPAIN.

    Oct 1, 2009, 00:00

  • PCN64 CHARACTERIZING RESOURCE USE AND TREATMENT COSTS FOR CHRONIC MYELOGENOUS LEUKEMIA (CML) IN THE UK (UK)

    Oct 1, 2009, 00:00

  • PCV142 ASSESSING THE QUALITY OF QUALITY OF LIFE MEASURES IN HEART FAILURE- A COMPARISON OF AVAILABLE INSTRUMENTS

    Oct 1, 2009, 00:00

  • PCN86 THE COST-EFFECTIVENESS OF BORTEZOMIB FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA-A NORDIC COMPARISON

    Oct 1, 2009, 00:00

  • PCV5 PROPHYLAXIS OF HEART TRANSPLANTATION REJECTION- FINANCIAL IMPACT ANALYSIS BY BRAZILIAN PUBLIC HEALTH CARE SYSTEM AND A REVIEW OF ECONOMIC EVALUATIONS STUDIES OF EVEROLIMUS, MMF (MYCOPHENOLATE MOFETIL) AND AZATHIOPRINE

    Oct 1, 2009, 00:00

  • PSY35 PROCESS MEASUREMENT IN IV-PCA AT UPPSALA UNIVERSITY HOSPITAL SWEDEN

    Oct 1, 2009, 00:00

  • PIN48 COMPARATIVE COST-EFFICACY ANALYSIS OF DARUNAVIR/R AND OTHER RITONAVIR-BOOSTED PROTEASE INHIBITORS FOR FIRST-LINE TREATMENT OF HIV-I INFECTION IN GERMANY

    Oct 1, 2009, 00:00

  • PMH17 PREVALENCE, INCIDENCE AND PERSISTENCE OF ANTIDEPRESSANT DRUG PRESCRIBING IN THE ITALIAN GENERAL POPULATION- RETROSPECTIVE DATABASE ANALYSIS

    Oct 1, 2009, 00:00

  • PSY50 THE EFFECT OF OBESITY ON PHYSICAL AND MENTAL HEALTH

    Oct 1, 2009, 00:00

  • DE3 HAVE RECENT PHARMACEUTICAL REFORMS DAMAGED RD?

    Oct 1, 2009, 00:00

  • AC3 NON-ADHERENCE IN OUTPATIENT THROMBOSIS PROPHYLAXIS AFTER MAJOR ORTHOPAEDIC SURGERY

    Oct 1, 2009, 00:00

  • EE6 INCORPORATING EQUITY IN COST-EFFECTIVENESS ANALYSIS- A SYSTEMATIC REVIEW

    Oct 1, 2009, 00:00

  • PSS42 INTERVENTIONAL PROCEDURES IN GLAUCOMA- RESOURCES AND COSTS IN FIVE EUROPEAN COUNTRIES

    Oct 1, 2009, 00:00

  • PIH11 SOCIO-ECONOMIC ASPECTS OF THE PRENATAL DIAGNOSIS OF CYTOMEGALOVIRUS (CMV) INFECTION IN GERMANY- A BURDEN OF DISEASE STUDY

    Oct 1, 2009, 00:00

  • CN7 TREATMENT VARIATION COMPLICATES REAL-WORLD PHARMACOECONOMICS- DAILY CLINICAL PRACTICE OF BORTEZOMIB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA

    Oct 1, 2009, 00:00

  • PIN57 A COMPARISON OF THE COST-EFFECTIVENESS OF THE 13-VALENT (PCVI3) AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN THE UK

    Oct 1, 2009, 00:00

  • PMS15 ECONOMIC IMPACT OF BIOTHERAPIES FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN FRANCE

    Oct 1, 2009, 00:00

  • PHP49 PALLIATIVE CARE AND ITS REIMBURSEMENT FOR OUTPATIENT SERVICES IN GERMANY-A SURVEY AMONG OFFICE-BASED PHYSICIANS

    Oct 1, 2009, 00:00

  • PCN75 COST-EFFECTIVENESS OF THALIDOMIDE COMBINED WITH MELPHALAN AND PREDNISONE IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA IN WALES

    Oct 1, 2009, 00:00

  • PMC22 DEVELOPMENT OF A SENSITIVE RESOURCE USE QUESTIONNAIRE

    Oct 1, 2009, 00:00

  • PMH42 COST-EFFECTIVENESS ANALYSIS OF OLANZAPINE LONG-ACTING INJECTION COMPARED WITH RISPERIDONE LONG-ACTING INJECTION IN THE TREATMENT OF SCHIZOPHRENIA IN NORWAY

    Oct 1, 2009, 00:00

  • PCV74 INCREMENTAL COSTS OF HYPERTENSION, HYPERGLYCEMIA, HYPERLIPIDEMIA, AND THEIR COMBINATIONS

    Oct 1, 2009, 00:00

  • PCV2 PREDICTED OPTIMAL LIPID VALUE ATTAINMENT RATES WITH THE CO-ADMINISTRATION OF FENOFIBRIC ACID AND A STATIN COMPARED TO STATIN MONOTHERAPY IN HISPANIC PATIENTS WITH MIXED DYSLIPIDEMIA

    Oct 1, 2009, 00:00

  • PCN133 POPULATION PREFERENCES FOR TREATMENT OUTCOMES IN CHRONIC LYMPHOCYTIC LEUKEMIA

    Oct 1, 2009, 00:00

  • PSS37 QUALITY OF LIFE IN CHRONIC HAND ECZEMA AS MEASURED BY THE DERMATOLOGY LIFE QUALITY INDEX

    Oct 1, 2009, 00:00

  • PCV97 COST-EFFECTIVENESS OF IVABRADINE IN PATIENTS WITH CHRONIC STABLE ANGINA IN A DUTCH SETTING

    Oct 1, 2009, 00:00

  • PMS7 DOSING PATTERN COMPARISON BETWEEN DULOXETINE AND PREGABALIN AMONG PATIENTS WITH FIBROMYALGIA

    Oct 1, 2009, 00:00

  • PDB29 PHARMACOECONOMIC CONSEQUENCES OF LOSARTAN THERAPY IN PATIENS UNDERGOING DIABETIC END-STAGE RENAL DISEASE

    Oct 1, 2009, 00:00

  • PG110 ECONOMIC EVALUATION OF A MULTIDISCIPLINARY SUPPORT PROGRAM IN HEPATITIS C TREATMENT- PRELIMINARY RESULTS

    Oct 1, 2009, 00:00

  • PCV4 COST AND OUTCOME ANALYSIS COMPARING PTCA CABG IN LOW AND HIGH RISK PATIENTS

    Oct 1, 2009, 00:00

  • PRS20 ECONOMIC EVALUATION OF THE IMPACT OF THE MEXICO CITYS NON-SMOKERS HEALTH PROTECTION ACT

    Oct 1, 2009, 00:00

  • PMS92 EXPOSURE TO OSTEOPOROSIS MEDICATION IN MEN

    Oct 1, 2009, 00:00

  • PDB44 EXAMINING THE RELATIONSHIP BETWEEN GLYCEMIC CONTROL AND MEDICATION ADHERENCE IN DIABETIC PATIENTS

    Oct 1, 2009, 00:00

  • PHP34 USING DISCRETE CHOICE EXPERIMENT MODELLING TO ASSESS PREFERENCES FOR HEALTH SYSTEM CHARACTERISTICS IN THE UNITED KINGDOWM AND AUSTRALIA

    Oct 1, 2009, 00:00

  • PMH68 IMPACT OF DEMENTIA UPON CAREGIVER EMPLOYMENT QUALITY OF LIFE

    Oct 1, 2009, 00:00

  • PRS21 COST-EFFECTIVENESS ANALYSIS OF XOLAIR UNDER REAL LIFE CONDITIONS IN BELGIAN PATIENTS WITH SEVERE ALLERGIC ASTHMA

    Oct 1, 2009, 00:00

  • PG123 STAPLED HAEMORRHOIDOPEXY IN THE TREATMENT OF HAEMORRHOIDAL PROLAPSE-COMPARISON OF HTA REPORTS, FOR TWO ITALIAN REGIONS

    Oct 1, 2009, 00:00

  • PIN4 SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF IMIQUIMOD 5% CREAM FOR THE TREATMENT OF EXTERNAL GENITAL WARTS

    Oct 1, 2009, 00:00

  • PHP13 CALCULATION OF DELAY OF DECISION-MAKING ON PHARMACEUTICAL REIMBURSEMENT IN SIMPLIFIED PROCEDURE IN HUNGARY

    Oct 1, 2009, 00:00

  • MO10 EARLY MODELLING- METHODS IN THE ECONOMIC ANALYSIS OF PRE-PHASE II PRODUCTS

    Oct 1, 2009, 00:00

  • PRS30 IMPACT OF OCULAR SYMPTOMS ON RESOURCE UTILISATION AND WORK PRODUCTIVITY IN MANAGEMENT OF AR-AN OBSERVATIONAL, CROSS SECTIONAL STUDY IN 4 COUNTRIES IN EUROPE

    Oct 1, 2009, 00:00

  • PDB66 PAYING FOR COSTLY PHARMACEUTICALS-REIMBURSEMENT STATUS OF LONG-ACTING INSULIN ANALOGUES IN SELECTED DEVELOPED COUNTRIES

    Oct 1, 2009, 00:00

  • PCN34 QUALITY OF LIFE IN DIFFERENT STAGES OF COLORECTAL PATIENTS ATTENDED AT THE SOCIAL SECURITY MEXICAN INSTITUTE

    Oct 1, 2009, 00:00

  • PCN32 IMPLEMENTATION OF CLINICAL INTERVENTION REPORTING SYSTEM FOR PHARMACISTS

    Oct 1, 2009, 00:00

  • PSY21 COST STUDY OF HAEMOPHILIA IN MOROCCO

    Oct 1, 2009, 00:00

  • PND18 COST-EFFECTIVENESS OF A NEW ABSORBABLE HYDROGEL FOR THE PREVENTION OF CSF LEAKS IN FRENCH HOSPITALS

    Oct 1, 2009, 00:00

  • PMS11 PERCEPTIONS OF TREATMENT OUTCOMES AMONG NEW USERS OF TNF ANTAGONISTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

    Oct 1, 2009, 00:00

  • MO3 R THERE ANY DIFFERENCES BETWEEN EXCEL AND R? COMPARISON OF ICER ESTIMATES AND CEACS OBTAINED FROM A MODEL IMPLEMENTED IN MICROSOFT EXCEL AND R

    Oct 1, 2009, 00:00

  • PCN24 CLINICAL OUTCOMES AND HEALTH CARE RESOURCE UTILISATION OF PATIENTS RECEIVING LAPATINIB FOR BREAST CANCER IN FRANCE- THE LAPS STUDY (LAPATINIB ATU PARCOURS DE SOINS)

    Oct 1, 2009, 00:00

  • PMH23 LABELLED DRUG-RELATED HEALTH PUBLIC EXPENDITURE IN RELATION TO GROSS DOMESTIC PRODUCT IN EUROPE

    Oct 1, 2009, 00:00

  • PCN103 PHARMACOECONOMIC ANALYSIS OF THE ADDITION OF RITUXIMAB TO FLUDARABINE-CYCLOPHOSPHAMIDE REGIMEN IN THE FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA PATIENTS IN SPAIN

    Oct 1, 2009, 00:00

  • PCV60 BUDGET IMPACT MODEL FOR DETERMINING THE HOSPITAL COSTS OF INTRODUCING PRASUGREL FOR THE LONG TERM TREATMENT OF ACUTE CORONARY SYNDROME TREATED BY PERCUTANEOUS CORONARY INTERVENTION IN FRANCE

    Oct 1, 2009, 00:00

  • PND14 COSTS OF ILLNESS IN PARKINSONS DISEASE IN SIX EUROPEAN COUNTRIES

    Oct 1, 2009, 00:00

  • PCN40 COST OF MANAGING ADVERSE EVENTS IN THE TREATMENT OF FIRST LINE METASTASIC RENAL CELL CARCINOMA- BEVACIZUMAB + INTERFERON ALPHA-2A COMPARED WITH SUNITINIB IN SPAIN

    Oct 1, 2009, 00:00

  • PCN23 PHARMACOEPIDEMIOLOGY OF PATIENTS TREATED WITH TEMOZOLOMIDE

    Oct 1, 2009, 00:00

  • PND10 COST ANALYSIS OF ACTIVA RC- RECHARGABLE NEUROESTIMULATOR FOR DEEP BRAIN ESTIMULATION THERAPY (DBS)

    Oct 1, 2009, 00:00

  • PDB12 ADHERENCE TO GLIMEPIRIDE FOR TYPE 2 DIABETICS IN COLOMBIA

    Oct 1, 2009, 00:00

  • PCN169 REVIEW OF THE DECISIONS OF HEALTH TECHNOLOGY ASSESSMENT AGENCIES FOR CAPECITABINE FOR THE TREATMENT OF BREAST CANCER

    Oct 1, 2009, 00:00

  • PHP14 A POLICY ANALYSIS OF THE PORTUGUESE GENERIC MEDICINES MARKET

    Oct 1, 2009, 00:00

  • PND36 HEALTH-RELATED QUALITY OF LIFE, EDSS AND TIMED 25-FOOT WALK IN A MULTIPLE SCLEROSIS POPULATION OF A REAL-WORLD OBSERVATIONAL OUTCOMES STUDY- BASELINE DATA FROM ROBUST

    Oct 1, 2009, 00:00

  • HP7 FACTORES PREDICTIVOS DEL XICO

    Oct 1, 2009, 00:00

  • PIN7 BUDGETARY IMPACT OF ADDING DORIPENEM TO A HOSPITAL FORMULARY IN GERMANY

    Oct 1, 2009, 00:00

  • PCV164 PRESSURES FACED BY PEOPLE WHO CARE FOR SOMEBODY DIAGNOSED WITH A CARDIOVASCULAR CONDITION

    Oct 1, 2009, 00:00

  • PCV78 ONE-YEAR HEALTH CARE COSTS FOR ACUTE CORONARY SYNDROME PATIENTS WITH DIFFERENT TREATMENT STRATEGIES DURING THE INITIAL HOSPITALIZATION

    Oct 1, 2009, 00:00

  • PDB56 THE IMPACT OF STARTING INSULIN GLARGINE VERSUS INSULIN DETEMIR ON QUALITY OF LIFE (QOL) AND TREATMENT SATISFACTION (TS) IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON ORAL GLUCOSE-LOWERING DRUGS (OGLDS)

    Oct 1, 2009, 00:00

  • PSY18 THE BURDEN OF OBESITY IN ONTARIO

    Oct 1, 2009, 00:00

  • PDB14 UTILIZACIN Y GASTOS EN SERVICIOS DE SALUD

    Oct 1, 2009, 00:00

  • PND25 COST-EFFECTIVENESS OF MEMANTINE IN THE TREATMENT OF MODERATE TO SEVERE ALZHEIMERS DISEASE IN NORWAY

    Oct 1, 2009, 00:00

  • PMC11 IMPUTE INCOMPLETE PATIENT-LEVEL MEDICAL COSTS

    Oct 1, 2009, 00:00

  • PSS2 COSTO-EFECTIVIDAD DEL USO DE ETANERCEPT VS LOS ANTICUERPOS MONOCLONALES ANTI-TNF EN PACIENTES CON PSORIASIS EN PLACAS EN MXICO

    Oct 1, 2009, 00:00

  • CN3 COST-EFFECTIVENESS OF SORAFENIB IN UNRESECTABLE AND/OR METASTATIC RENAL CELL CARCINOMA IN TURKEY

    Oct 1, 2009, 00:00

  • PCN21 ESTUDIO DE COSTO EFECTIVIDAD DEL USO DE TRASTUZUMAB COMO TRATAMIENTO ADYUVANTE DEL CA DE COLOMBIA, DESDE EL PUNTO DE VISTA DEL PAGADOR

    Oct 1, 2009, 00:00

  • PCV144 HEALTH-RELATED QUALITY OF LIFE AND RESOURCE USE IN PATIENTS WITH METABOLIC SYNDROME- A COMPARISON OF THE UNITED STATES, EUROPE, AND JAPAN

    Oct 1, 2009, 00:00

  • PMS98 DEVELOPMENT AND VALIDATION OF A DISEASE MODEL FOR POSTMENOPAUSAL OSTEOPOROSIS

    Oct 1, 2009, 00:00

  • MC5 TOWARD AN ECONOMIC FRAMEWORK FOR UNDERSTANDING PERFORMANCE-BASED RISK-SHARING AGREEMENTS FOR INNOVATIVE MEDICAL PRODUCTS

    Oct 1, 2009, 00:00

  • PIN16 COST-EFFECTIVENESS OF HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV-7) IN MEXICO

    Oct 1, 2009, 00:00

  • PHP1 TRANSPARENCY IN LATIN AMERICAN HTA- HOW DO WE MEASURE SUCCESS?

    Oct 1, 2009, 00:00

  • PCN37 ABRANGDE

    Oct 1, 2009, 00:00

  • PUK3 FORECASTING SPANISH RENAL REPLACEMENT THERAPY TRENDS FROM REGISTRY DATA- A QUANTILE REGRESSION APPROACH

    Oct 1, 2009, 00:00

  • CS1 COST-EFFECTIVENESS ANALYSIS OF A CERVICAL CANCER VACCINE IN FIVE LATIN AMERICAN COUNTRIES

    Oct 1, 2009, 00:00

  • PCN9 DEVELOPMENT OF SERUM TESTS FOR COLORECTAL CANCER SCREENING

    Oct 1, 2009, 00:00

  • MC2 SELF-PERCEPTION OF HEALTH IN LATIN AMERICA

    Oct 1, 2009, 00:00

  • PMS82 VALIDITY AND RELIABILITY OF A HEATH RELATED QUALITY OF LIFE QUESTIONNAIRE - SOCIAL FUNCTIONING SCALE FOR TURKISH MSDS PATIENTS

    Oct 1, 2009, 00:00

  • PCV8 PREVALENCE OF PERIPHERAL ARTERIAL DISEASE IN SUBJECTS WITH A MODERATE CVD RISK, WITH NO OVERT VASCULAR DISEASES NOR DIABETES MELLITUS. THE PANDORA SURVEY-BELGIUM RESULTS

    Oct 1, 2009, 00:00

  • PHP68 FIRST IMPRESSIONS FROM A SHORT TRAINING COURSE IN RATIONAL USE OF DRUGS FOR THE PHARMACOLOGISTS IN THE PHARMACY SCHOOLS IN TURKEY

    Oct 1, 2009, 00:00

  • PCN155 'PATIENT ACCESS SCHEMES'-THE USE OF RISK-SHARING IN THE UK

    Oct 1, 2009, 00:00

  • PMS32 ASSESSMENT OF THE TOTAL DIRECT MEDICAL COST OF PATIENTS IN SECOND-LINE TNF INHIBITOR THERAPY AND OF THE RESPECT OF CLINICAL PRACTICE RECOMMENDATIONS

    Oct 1, 2009, 00:00

  • PSY4 CHALLENGES IN USING THE LITERATURE TO ESTIMATE THE OUTCOMES OF CURRENT RISK STRATIFICATION METHODS IN ADULT PATIENTS WITH PRIMARY ACUTE MYELOID LEUKEMIA

    Oct 1, 2009, 00:00

  • PSS21 COST-EFFECTIVENESS OF A NEW TOPICAL PRESERVATIVE-FREE OPHTHALMIC ANTIBIOTIC TREATMENT WITH MOXIFLOXACIN IN THE NETHERLANDS

    Oct 1, 2009, 00:00

  • PDB60 EVALUATION OF THE PATIENTS PERSPECTIVE OF MEDICAL CARE IN TYPE 2 DIABETES DISEASE MANAGEMENT PROGRAMS

    Oct 1, 2009, 00:00

  • PCV38 HOSPITALIZATION AND MORTALITY IN ADVANCED-AGE PATIENTS WITH ATRIAL FIBRILLATION/ATRIAL FLUTTER BUT WITHOUT HEART FAILURE IN THE UNITED STATES

    Oct 1, 2009, 00:00

  • PSS10 COST OF MODERATE TO SEVERE PSORIASIS PATIENTS IN SPAIN

    Oct 1, 2009, 00:00

  • PIH23 ECONOMIC EVALUATION OF ATOSIBAN COMPARED TO BETAMIMETICS FOR THE TREATMENT OF PRETERM LABOUR IN AUSTRIA

    Oct 1, 2009, 00:00

  • PDB47 HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH TYPE 2 DIABETES OVER THE 24 MONTHS FOLLOWING INITIATION OF INSULIN

    Oct 1, 2009, 00:00

  • PMS2 ANIDE SOB A PERSPECTIVA DE UM PAGADOR PRIVADO NO BRASIL

    Oct 1, 2009, 00:00

  • PHP19 APPLYING 'VALUE BASED' PRICING TO REGENERATIVE MEDICINE BASED PHARMACEUTICALS

    Oct 1, 2009, 00:00

  • PMS6 HEALTH ASSESSMENT QUESTIONNAIRE-DISABILITY INDEX (HAQ-DI) SCORES IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOCILIZUMAB PLUS CONVENTIONAL ANTI-RHEUMATIC DRUGS

    Oct 1, 2009, 00:00

  • PCV165 CHANGES IN THE COST-EFFICACY OF STATINS IN SPAIN AFTER THE INTRODUCTION OF GENERICS AND REFERENCE PRICES

    Oct 1, 2009, 00:00

  • PMC17 SHOULD INDIRECT COSTS OF ILLNESS BE INCLUDED IN PHARMACOECONOMIC ANALYSIS- SURVEY AMONG POLISH DECISION MAKERS AND EXPERTS

    Oct 1, 2009, 00:00

  • PCN117 COST-UTILITY MODEL TO EVALUATE ADJUVANT CHEMOTHERAPY FOR EARLY BREAST CANCER IN THE USA

    Oct 1, 2009, 00:00

  • PCV29 OUTCOMES ASSESSMENT IN LOW HIGH RISK P.T.C.A. PATIENTS

    Oct 1, 2009, 00:00

  • PCN63 REVIEW OF THE ECONOMIC IMPACT OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY

    Oct 1, 2009, 00:00

  • PCV40 ACUTE MYOCARDIAL AND CEREBRAL INFARCTION REGARDING TO SEASONAL, WEEKLY AND DAILY VARIATION IN CASE OF HUNGARY

    Oct 1, 2009, 00:00

  • PIN69 A PATIENT SATISFACTION QUESTIONNAIRE FOR ASSESSING PHARMACEUTICAL CARE SERVICES IN NIGERIAN HIV CLINICS

    Oct 1, 2009, 00:00

  • PIH9 PREVALENCE AND BURDEN OF ILLNESS OF MENOPAUSE- A CANADIAN OBSERVATIONAL STUDY

    Oct 1, 2009, 00:00

  • PCN6 A COMPARISON OF CLINICAL EFFICACY AND SAFETY OF LENOGRASTIM AND FILGRASTIM IN THE STEM CELL MOBILIZATION

    Oct 1, 2009, 00:00

  • PCN84 COST-EFFECTIVENESS ANALYSES OF DOCETAXEL VERSUS PACLITAXEL ONCE WEEKLY IN PATIENTS WITH METASTATIC BREAST CANCER PROGRESSED AFTER ANTHRACYCLINE CHEMOTHERAPY IN SPAIN

    Oct 1, 2009, 00:00

  • CS18 ECONOMIC EVALUATION OF BARIATRIC SURGERY AS TREATMENT FOR OBESITY AND ASSOCIATED COMORBIDITIES-ESTIMATION BY DISCRETE EVENT SIMULATION

    Oct 1, 2009, 00:00

  • ISPOR 2nd Latin America Conference Author Index

    Oct 1, 2009, 00:00

  • PMS84 IMPACT OF CERTOLIZUMAB PEGOL (CZP) ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)- RHEUMATOID ARTHRITIS (RA) PATIENTS APPROACH POPULATION US NORMS IN MENTAL HEALTH AND VITALITY DOMAINS

    Oct 1, 2009, 00:00

  • PMS61 SHORT-TERM DISABILITY ASSOCIATED WITH HIP, NON-VERTEBRAL, AND VERTEBRAL FRACTURES IN THE UNITED STATES

    Oct 1, 2009, 00:00

  • PMH44 COST AND EFFECTIVENESS OF FLUPENTIXOL COMPARED TO OTHER FIRST AND SECOND GENERATION ANTIPSYCHOTIC AGENTS FOR THE TREATMENT OF SCHIZOPHRENIA IN ROUTINE CARE

    Oct 1, 2009, 00:00

  • WP2 VALUE OF POSTOPERATIVE ACUTE PAIN CARE FOR PATIENTS OPERATED BY LAPAROTOMY IN A DEPARTMENT OF DIGESTIVE SURGERY IN A FRENCH UNIVERSITY HOSPITAL- A WILLINGNESS TO PAY STUDY

    Oct 1, 2009, 00:00

  • PCV1 MISDIAGNOSIS AND MISTREATMENT OF A COMMON SIDE-EFFECT-ACE INHIBITOR INDUCED COUGH

    Oct 1, 2009, 00:00

  • PCV145 IMPACT OF HOSPITALIZATION ON HEALTH-RELATED QUALITY OF LIFE IN ATRIAL FIBRILLATION PATIENTS

    Oct 1, 2009, 00:00

  • PMC27 IDENTIFYING ECONOMIC EVALUATIONS IN MEDLINE AND EMBASE- HOW WELL DO PUBLISHED SEARCH FILTERS PERFORM?

    Oct 1, 2009, 00:00

  • PMS45 COST-EFFECTIVENESS OF BALLOON KYPHOPLASTY IN PATIENTS WITH SYMPTOMATIC VERTEBRAL COMPRESSION FRACTURES IN A UK SETTING

    Oct 1, 2009, 00:00

  • PMS4 EUROQOL-5 DIMENSION HEALTH STATUS QUESTIONNAIRE RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED PHASE 3 STUDY OF TAPENTADOL EXTENDED RELEASE (ER) FOR THE MANAGEMENT OF CHRONIC OSTEOARTHRITIS KNEE PAIN

    Oct 1, 2009, 00:00

  • PMS48 PHARMACOECONOMIC MODEL FOR TREATING OSTEOPOROSIS WITH ALPHACALCIDOL IN GERMANY

    Oct 1, 2009, 00:00

  • PCN158 LUXEMBOURG LUNG CANCER PROJECT- POTENTIAL CLINICAL AND ECONOMIC IMPACT OF BIOMARKER DEVELOPMENT IN THE DIAGNOSIS AND TREATMENT OF SINGLE PULMONARY NODULES IN LUXEMBOURG

    Oct 1, 2009, 00:00

  • PHP1 THE COMMERCIALIZATION OF HEALTH CARE ALLOCATION- CONSUMERS TOTAL AND DISTRIBUTIONAL HEALTH OUTCOME PERCEPTIONS AND ATTITUDE TOWARDS FLEXIBLE CARE ACCESS PRICING STRATEGIES BY HOSPITALS

    Oct 1, 2009, 00:00

  • PCN159 TREND OF METASTASECTOMY AND CHEMO- AND BIOLOGIC THERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER

    Oct 1, 2009, 00:00

  • PCV11 UNDERSTANDING THE IMPACT OF STATIN TITRATION; A MODELLING APPROACH

    Oct 1, 2009, 00:00

  • PDB15 COST OF AN EPISODE OF DIABETIC FOOT ULCER IN SPAIN

    Oct 1, 2009, 00:00

  • PCN150 THE RELATIONSHIP BETWEEN DRUG UTILIZATION AND OUT OF POCKET EXPENSES FOR ORAL ANTINEOPLASTICS COMPARED TO A MARKET BASKET OF COMMONLY USED DRUGS

    Oct 1, 2009, 00:00

  • PMC25 CLINICAL HISTORY, RESOURCE UTILIZATION, AND OTHER PATIENTREPORTED OUTCOMES (PROS) IN MIGRAINEURS- AN ADAPTABLE WEB-BASED METHODOLOGY FOR THE DESIGN, IMPLEMENTATION AND CONDUCT OF A MULTI-NATIONAL SURVEY OF PATIENTS

    Oct 1, 2009, 00:00

  • PCN19 COST-EFFECTIVENESS ANALYSIS OF CLOFARABINE IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA IN MEXICO

    Oct 1, 2009, 00:00

  • PCN108 PHARMAECONOMIC EVALUATION OF THE USE OF PROLONGED LIBERATION HIDROMORFONE IN THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN FOR CANCER AT AN INSTITUTIONAL LEVEL IN MEXICO

    Oct 1, 2009, 00:00

  • PCN35 SYSTEMATIC REVIEW OF THE IMPACT OF CHEMOTHERAPY ON PATIENT REPORTED OUTCOMES IN ADVANCED NON-SMALL-CELL LUNG CANCER

    Oct 1, 2009, 00:00

  • PMH55 DEPRESSION TREATMENT ADHERENCE AMONG DEPRESSION PATIENTS WITH COMORBIDITY

    Oct 1, 2009, 00:00

  • PSS34 TOOLS TO HELP DIAGNOSIS OF ATOPIC DERMATITIS- A NEED IN PUBLIC HEALTH

    Oct 1, 2009, 00:00

  • PCV96 COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN CHRONIC STABLE ANGINA PATIENTS IN A FINNISH SETTING

    Oct 1, 2009, 00:00

  • PCN66 COST EVALUATION OF THE CROSS PROTECTION DIFFERENCE BETWEEN THE BIVALENT AND QUADRIVALENT HPV VACCINE AGAINST CERVICAL CANCER WITHIN EUROPEAN COUNTRIES

    Oct 1, 2009, 00:00

  • PMH59 FURTHER VALIDITY EVIDENCES OF THE GENERALIZED ANXIETY DISORDER-7 SCALE (GAD-7)

    Oct 1, 2009, 00:00

  • PCN4 BISPHOSPHONATES AND TIME TO OSTEONECROSIS DEVELOPMENT. A SYSTEMATIC REVIEW

    Oct 1, 2009, 00:00

  • PMH6 COSTO-EFECTIVIDAD DE OCHO MEDICAMENTOS ANTIPSICTICOS EN COLOMBIA

    Oct 1, 2009, 00:00

  • PCN102 COST EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2+VE BREAST CANCER IN ITALY UTILIZING FOLLOW UP DATA

    Oct 1, 2009, 00:00

  • PCN160 MODELLING NUMBER OF CANCER PATIENTS POTENTIALLY TREATED WITH TARGETED PHARMACOTHERAPY IN THE CZECH REPUBLIC

    Oct 1, 2009, 00:00

  • PCN137 ONCOLOGY PATIENT-REPORTED CLAIMS- MAXIMISING THE CHANCE FOR SUCCESS

    Oct 1, 2009, 00:00

  • PIN18 THE COST BURDEN OF ACUTE GASTROENTERITIS IN INFANTS AND YOUNG CHILDREN ATTENDING DAYCARE CENTRES IN FRANCE

    Oct 1, 2009, 00:00

  • PIH19 COST-EFFECTIVENESS ANALYSIS OF THE NEW FERTILITY TREATMENT (RFSH+RLH)

    Oct 1, 2009, 00:00

  • PND15 THE POTENTIAL ECONOMIC IMPACT OF GENERIC SUBSTITUTION OF TOPIRAMATE ON HEALTH CARE COSTS IN THE G4 EUROPEAN COUNTRIES

    Oct 1, 2009, 00:00

  • PCV89 PRASUGREL COST-EFFECTIVE RELATIVE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE? A MODEL-BASED ANALYSIS

    Oct 1, 2009, 00:00

  • PCV143 EXPLORING PATIENTS SATISFACTION WITH ANTICOAGULANT TREATMENT BY APPLYING STRUCTURAL EQUATION MODELS TO THE PERCEPTION OF ANTICOAGULANT TREATMENT QUESTIONNAIRE (PACT-Q)

    Oct 1, 2009, 00:00

  • PMS20 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF INTRA-ARTICULAR SODIUM HYALURONATE VERSUS TOTAL ARTHROPLASTY IN THE TREATMENT OF KNEE OSTEOARTHRITIS UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE

    Oct 1, 2009, 00:00

  • PIH41 PRESCRIPTION PATTERNS AND EXPENDITURE OF LONG-TERM BENZODIAZEPINE TREATMENT IN ELDERLY OUTPATIENTS IN TAIWAN

    Oct 1, 2009, 00:00

  • PHP36 HEALTH ECONOMICS DATA- USE AND PERCEIVED VALUE IN U.S. PAYERS FORMULARY DECISIONS

    Oct 1, 2009, 00:00

  • PIN27 COST-EFFECTIVENESS OF LINEZOLID VS. VANCOMYCIN AND TEICOPLANIN IN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS IN CZECH REPUBLIC

    Oct 1, 2009, 00:00

  • PIN36 SCREENING OF MIGRANTS FOR CHRONIC HEPATITIS B VIRUS INFECTION- A COST-EFFECTIVENESS ANALYSIS

    Oct 1, 2009, 00:00

  • PIN42 COST-EFFECTIVENESS OF SWITCHING STRATEGIES FROM A 7-VALENTTO A 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE

    Oct 1, 2009, 00:00

  • PSS38 INFLUENCE OF DEPRESSION ON HEALTH RELATED QUALITY OF LIFE IN PSORIASIS- RESULTS FROM AN OPEN LABEL STUDY OF ADALIMUMAB IN PATIENTS WITH PSORIASIS

    Oct 1, 2009, 00:00

  • PND27 A DISCRETE EVENT SIMULATION OF PREGABALIN COMPARED TO USUAL CARE IN REFRACTORY NEUROPATHIC PAIN

    Oct 1, 2009, 00:00

  • PCN59 REAL-WORLD COSTS OF ADJUVANT TREATMENT FOR STAGE III COLON CANCER PATIENTS IN THE NETHERLANDS

    Oct 1, 2009, 00:00

  • PCN57 EVALUATION OF THE COMPLICATION RATE AND COST OF TREATMENT ACCORDING TO THE MASCC INDEX IN PATIENTS WITH FEBRILE NEUTROPENIA

    Oct 1, 2009, 00:00

  • CASE4 ASSESSMENT AND APPRAISAL IN THE NETHERLANDS

    Oct 1, 2009, 00:00

  • PMS86 CERTOLIZUMAB PEGOL DEMONSTRATES SIGNIFICANT IMPROVEMENTS IN THE PRODUCTIVITY OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS, PARTICULARLY IN THE HOUSEHOLD

    Oct 1, 2009, 00:00

  • CN4 COST-EFFECTIVENESS OF PEMETREXED IN FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PORTUGAL

    Oct 1, 2009, 00:00

  • PDB7 HOSPITALIZACIONES POR INSUFICIENCIA CARDN VS. LOS DE SU TRATAMIENTO

    Oct 1, 2009, 00:00

  • PG115 TREATMENT OF MODERATE TO SEVERE PAIN WITH OXYCODONE/ NALOXONE TO REDUCE OPIOID-INDUCED CONSTIPATION- A COST-UTILITY ANALYSIS IN BELGIUM AND THE NETHERLANDS

    Oct 1, 2009, 00:00

  • PSS2 COMPARISON OF OUTCOMES FOR MULTIFOCAL INTRA-OCULAR LENSES (MIOLS)- A META-ANALYSIS

    Oct 1, 2009, 00:00

  • PMS41 COST-EFFECTIVENESS OF TNF-ALPHA BLOCKERS IN REAL-WORLD SETTING OF CZECH REGISTRY

    Oct 1, 2009, 00:00

  • PIN63 COST-UTILITY ANALYSIS OF PNEUMOCOCCAL CONJUGATE VACCINES IN GERMANY

    Oct 1, 2009, 00:00

  • PIN19 ECONOMIC EVALUATION OF RUBELLA AND CONTROL STRATEGIES DURING AN OUTBREAK IN FORTALEZA (CEAR), BRAZIL, 2007

    Oct 1, 2009, 00:00

  • PMS3 PROPORTION OF PATIENTS WITH OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN PERFORMING A BONE MINERAL DENSITY DIAGNOSIS MEASUREMENT- THE PRESAGE STUDY

    Oct 1, 2009, 00:00

  • PHP97 THE PHARMACOECONOMIC ANALYSIS OF EXTEMPORAL MEDICINES USED FOR TREATMENT OF DISEASES AT CHILDREN IN UKRAINE

    Oct 1, 2009, 00:00

  • PRS26 COST-EFFECTIVENESS OF GRAZAX IN THE PAEDIATRIC POPULATION FOR THE TREATMENT OF GRASS POLLEN INDUCED RHINOCONJUNCTIVITIS IN GERMANY

    Oct 1, 2009, 00:00

  • PSS19 CEFOVECIN AS TREATMENT OF SUPERFICIAL PYODERMA, WOUNDS AND ABSCESSES IN DOGS- ESTIMATION OF THE HEALTH AND ECONOMIC IMPACT OF ELIMINATING ORAL MEDICATION NONCOMPLIANCE IN THE UNITED STATES

    Oct 1, 2009, 00:00

  • PCV163 GENDER-BASED DIFFERENCES IN HEALTH CARE COSTS AMONG ACS PATIENTS- AN APPLICATION OF THE BLINDER-OAXACA DECOMPOSITION

    Oct 1, 2009, 00:00

  • PCN5 ANNICA- A PERSPECTIVA DA FONTE PAGADORA

    Oct 1, 2009, 00:00

  • PMS53 ECONOMIC EVALUATION OF TRAMADOL/PARACETAMOL COMBINATION TABLETS VS NSAIDS FOR OSTEOARTHRITIS PAIN IN SPAIN

    Oct 1, 2009, 00:00

  • PSS35 DEVELOPMENT AND VALIDATION OF A TREATMENT SATISFACTION QUESTIONNAIRE OF HAND SKIN DISEASES- THE DERMSAT QUESTIONNAIRE

    Oct 1, 2009, 00:00

  • PMC9 REDUCING BIAS IN A RETROSPECTIVE CASE-CONTROL STUDY- AN APPLICATION OF PROPENSITY SCORE MATCHING

    Oct 1, 2009, 00:00

  • PHP13 ATENO DE LITERATURA

    Oct 1, 2009, 00:00

  • PIN39 COST-EFFECTIVENESS OF MASS VARICELLA VACCINATION IN FRANCE- ECONOMIC CONSEQUENCES OF AN INTENSIVE VACCINATION PROGRAM

    Oct 1, 2009, 00:00

  • PUK1 USE OF A BAYESIAN MIXED TREATMENT META ANALYSIS TO SUPPORT REIMBURSEMENT DECISION MAKING OF PHOSPHATE BINDER THERAPY IN END-STAGE RENAL DISEASE

    Oct 1, 2009, 00:00

  • AC2 SUCCESS FACTORS IMPROVING PATIENT COMPLIANCE BEHAVIOUR-EMPIRICAL FINDINGS FROM EUROPE

    Oct 1, 2009, 00:00

  • PMC30 HOW TO GAIN HIGH DATA QUALITY IN A NON-INTERVENTIONAL TRIAL TAKING THE LIVE-COM STUDY AS EXAMPLE

    Oct 1, 2009, 00:00

  • PCV120 DRONEDARONE IN ATRIAL FIBRILLATION- MODELING HEALTH OUTCOMES

    Oct 1, 2009, 00:00

  • PCN13 COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC) IN COLOMBIA (ONCOLGROUP STUDY)

    Oct 1, 2009, 00:00

  • PCV135 HEALTH STATUS IN AN ARGENTINIAN POPULATION SURVEY - RESULTS FROM THE NATIONAL RISK FACTOR SURVEY

    Oct 1, 2009, 00:00

  • PSS4 SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF IMIQUIMOD 5% CREAM FOR THE TREATMENT OF ACTINIC KERATOSES

    Oct 1, 2009, 00:00

  • PRS19 IS IT TIME FOR SMOKING CESSATION PRODUCTS TO BE REIMBURSABLE IN THAILAND?

    Oct 1, 2009, 00:00

  • CS10 ANLTIPLE REMITENTE RECIDIVANTE EN COLOMBIA

    Oct 1, 2009, 00:00

  • PSS33 DEVELOPMENT OF A NEW MEASURE FOR ASSESSING HEALTHRELATED QUALITY OF LIFE IN PATIENTES WITH PSOARIASIS- PSO-LIFE'

    Oct 1, 2009, 00:00

  • PSY5 A RETROSPECTIVE CHART REVIEW OF THE TREATMENT OF PHENYLKETONURIA IN THE UK AND ASSOCIATED CLINICAL AND HEALTH OUTCOMES

    Oct 1, 2009, 00:00

  • MO1 COHORT MODELLING-IS THE APPROACH TOO OLD FOR THE ELDERLY?

    Oct 1, 2009, 00:00

  • PHP73 APPLYING KEY PRINCIPLES FOR IMPROVED HEALTH TECHNOLOGY ASSESSMENT- AN ANALYSIS OF 14 HTA ORGANIZATIONS

    Oct 1, 2009, 00:00

  • PCV126 REDUCTION IN REHOSPITALIZATIONS AND ASSOCIATED COSTS WITHIN 30 DAYS AFTER DISCHARGE FROM HOSPITALIZATION FOR ACUTE CORONARY SYNDROMES AND PLANNED PCI WITH PRASUGREL VS. CLOPIDOGREL- RESULTS FROM THE TRITON-TIMI 38 TRIAL FOR PATIENTS ...

    Oct 1, 2009, 00:00

  • EE7 A DISCRETE CHOICE EXPERIMENT COMPARING PUBLIC AND DECISION-MAKER STATED PREFERENCES FOR PHARMACEUTICAL SUBSIDY DECISIONS

    Oct 1, 2009, 00:00

  • PRS40 IMPACT OF COUGH AND/OR SPUTUM SYMPTOMS ON HEALTH-RELATED QUALITY OF LIFE IN COPD PATIENTS- AN OBSERVATIONAL, CROSS-SECTIONAL STUDY IN EUROPE AND THE USA

    Oct 1, 2009, 00:00

  • PCN52 COSTS OF ADVANCED GASTRIC CANCER (AGC) IN BRAZIL FROM THE PUBLIC PAYER PERSPECTIVE

    Oct 1, 2009, 00:00

  • PSS32 VALIDATION AND ASSESSMENT OF MEASUREMENT INVARIANCE OF THE EYELASH SATISFACTION QUESTIONNAIRE (ESQ) IN US CANCER PATIENTS

    Oct 1, 2009, 00:00

  • PIN15 THE ECONOMIC IMPLICATION OF A RAPID DIAGNOSE AND EARLY SHIFT IN THERAPY IN PATIENTS WITH INVASIVE CANDIDA INFECTION

    Oct 1, 2009, 00:00

  • PMS69 ITEM REDUCTION AND VALIDATION OF A NEW ADHERENCE QUESTIONNAIRE IN OSTEOPOROTIC POST-MENOPAUSAL WOMEN- THE ADHERENCE EVALUATION OF OSTEOPOROSIS TREATMENT (ADEOS) QUESTIONNAIRE

    Oct 1, 2009, 00:00

  • PCN58 RESOURCES USED IN PATIENTS WITH ANEMIA INDUCED BY CHEMOTHERAPY REQUIRING BLOOD TRANSFUSIONS. EPICOST STUDY, PRELIMINARY RESULTS (ONVIDA GROUP)

    Oct 1, 2009, 00:00

  • PCV1 PREDICTED CARDIOVASCULAR EVENT REDUCTION WITH THE COADMINISTRATION OF FENOFIBRIC ACID AND LOW- OR MODERATEDOSE STATINS IN HISPANIC PATIENTS WITH MIXED DYSLIPIDEMIA

    Oct 1, 2009, 00:00

  • PCV119 COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN THE NETHERLANDS

    Oct 1, 2009, 00:00

  • PMC29 IMPACT OF MISSING DATA ON POTENTIAL CONFOUNDERS IN PERINATAL PHARMACOEPIDEMIOLOGIC STUDIES USING ADMINISTRATIVE DATABASES

    Oct 1, 2009, 00:00

  • PCV17 HOW DOES THE DUAL COMBINATION OF ARBS+HCTZ COMPARE TO OTHER DUAL COMBINATIONS IN THE TREATMENT OF HYPERTENSION?

    Oct 1, 2009, 00:00

  • PCV86 COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE IMPLANTATION IN HIGH-RISK PATIENTS WITH SYMPTOMATIC AORTIC VALVE STENOSIS IN FRANCE

    Oct 1, 2009, 00:00

  • PHP32 THE USEFULNESS AND CHALLENGES OF PATIENT ACCESS (RISK SHARING) SCHEMES IN THE UK

    Oct 1, 2009, 00:00

  • PHP18 COMPARATIVE ANALYSIS OF THE IMPACT OF POSITIVE DRUG LIST SYSTEM BETWEEN NEW DRUGS VS INCREMENTALLY MODIFIED DRUGS IN SOUTH KOREA

    Oct 1, 2009, 00:00

  • PHP4 USE OF FREE MEDICINE SAMPLES, DOCTOR PATIENT COMMUNICATION AND COST-RELATED NON-ADHERENCE AMONG OLDER ADULTS

    Oct 1, 2009, 00:00

  • PND16 ECONOMIC IMPACT OF GENERIC ENTRY OF TOPIRAMATE IN GERMANY- CONVERSION OF THE CANADIAN EXPERIENCE INTO THE SETTINGS OF GERMANY

    Oct 1, 2009, 00:00

  • PSS24 COST EFFECTIVENESS ANALYSIS OF TAFLUPROST COMPARED WITH LATANOPROST ON THE TREATMENT OF PRIMARY OPEN ANGLE GLAUCOMA IN SOUTH KOREA

    Oct 1, 2009, 00:00

  • PCV68 CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) COST OF ILLNESS IN THE PRIVATELY-INSURED POPULATION IN THE UNITED STATES

    Oct 1, 2009, 00:00

  • PCV55 BUDGET IMPACT ANALYSIS OF DIAGNOSTIC OF UNEXPLAINED AND/OR RECURRENT SYNCOPE WITH APPLICATION OF IMPLANTABLE LOOP RECORDER

    Oct 1, 2009, 00:00

  • PIN32 COST EFFECTIVENESS OF UNIVERSAL ROTAVIRUS VACCINATION IN IRELAND- A PRELIMINARY ANALYSIS

    Oct 1, 2009, 00:00

  • PMH24 ECONOMIC BENEFITS OF ESCITALOPRAM VERSUS DULOXETINE IN SPAIN

    Oct 1, 2009, 00:00

  • PMC37 COMPARISON OF RISK ADJUSTMENT MODELS IN OUTCOMES RESEARCH

    Oct 1, 2009, 00:00

  • PIH8 A BUDGET IMPACT ANALYSIS OF DIENOGEST IN TREATING ENDOMETRIOSIS ASSOCIATED PELVIC PAIN IN GERMANY

    Oct 1, 2009, 00:00

  • PDB14 THE BUDGET IMPACT ANALYSIS OF VILDAGLIPTIN IN TYPE 2 DIABETES IN POLAND

    Oct 1, 2009, 00:00

  • PCN30 THE BURDEN OF MULTIPLE MYELOMA- ASSESSMENT ON OCCURRENCE, OUTCOMES AND COST USING A RETROSPECTIVE LONGITUDINAL STUDY BASED ON ADMINISTRATIVE CLAIMS DATABASE

    Oct 1, 2009, 00:00

  • PMC3 CRITICAL REVIEW OF PUBLISHED COST EFFECTIVENESS ANALYSES OF ORAL TRIPTANS IN THE MANAGEMENT OF ACUTE MIGRAINE- DIFFERENT MEASURES OF EFFICACY EXTRACTED FROM THE SAME META-ANALYSIS

    Oct 1, 2009, 00:00

  • PMC1 RANKING HOSPITALS ACCORDING TO QUALITY

    Oct 1, 2009, 00:00

  • PCN77 COST-EFFECTIVENESS ANALYSIS OF TEMSIROLIMUS VS. SUNITINIB MALATE IN POOR PROGNOSIS METASTATIC RENAL CELL CARCINOMA (MRCC) IN PORTUGAL

    Oct 1, 2009, 00:00

  • PHP59 TRENDS IN COMPARATIVE EFFECTIVENESS OF TOP 20 HIGHEST SELLING DRUGS

    Oct 1, 2009, 00:00

  • PRS6 COST-EFFECTIVENESS OF FLUTICASONE PROPIONATE/SALMETEROL (500/50 MG) IN THE TREATMENT OF COPD IN BRAZILIAN PUBLIC SECTOR

    Oct 1, 2009, 00:00

  • PHP75 SCANNING THE HORIZON FOR NEW AND EMERGING OMIC TECHNOLOGIES

    Oct 1, 2009, 00:00

  • PCN138 INFORMATION NEEDS- A STUDY ABOUT ONCOLOGICAL PATIENTS IN THE ITALIAN CONTEXT

    Oct 1, 2009, 00:00

  • PRS9 THE IMPACT AND COSTS OF REIMBURSED SMOKING CESSATION USING VARENICLINE IN DENMARK

    Oct 1, 2009, 00:00

  • PDB35 LOWER TREATMENT COSTS WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN TYPE-2 DIABETES PATIENTS ON BASAL-BOLUS THERAPY UNDER REAL WORLD CONDITIONS IN GERMANY

    Oct 1, 2009, 00:00

  • PMS56 COST-UTILITY OF AUTOLOGOUS CHONDROCYTES IMPLANTATION USING CHONDROCELECT IN SYMPTOMATIC KNEE CARTILAGE DAMAGE IN BELGIUM

    Oct 1, 2009, 00:00

  • PIH33 DRUG USE BEFORE AND DURING PREGNANCY IN REPUBLIC OF SERBIA

    Oct 1, 2009, 00:00

  • PDB39 ECONOMIC ANALYSIS OF GLARGINE INSULIN AND DETEMIR INSULIN IN PATIENTS WITH TYPE I DIABETES MELLITUS IN MEXICO

    Oct 1, 2009, 00:00

  • PCN61 HOSPITAL BURDEN RELATED TO UPPER AERODIGESTIVE TRACT CANCERS IN FRANCE

    Oct 1, 2009, 00:00

  • PMS18 MANAGEMENT AND COST OF SCIATICA IN-HOSPITAL

    Oct 1, 2009, 00:00

  • PCV20 METABOLIC SYNDROME PATIENT COMPLIANCE WITH DRUG AND NON-DRUG TREATMENT

    Oct 1, 2009, 00:00

  • PCV72 ESTIMATING LIFETIME ECONOMIC BURDEN OF STROKE IN KOREA ACCORDING TO THE AGE OF ONSET- USING NATIONAL HEALTH INSURANCE CLAIMS DATABASE

    Oct 1, 2009, 00:00

  • PMS9 SECULAR DECREASES IN OSTEOPOROTIC FRACTURE RATES 1986-2006- A POPULATION-BASED ANALYSISxyq

    Oct 1, 2009, 00:00

  • PCN172 TREATMENT PATTERNS AMONG PATIENTS WITH ADVANCED BREAST CANCER PREVIOUSLY TREATED WITH AN ANTHRACYCLINE AND A TAXANE- A RETROSPECTIVE LONGITUDINAL STUDY

    Oct 1, 2009, 00:00

  • PIH39 VALIDITY AND RELIABILITY OF QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE FOR TURKISH WOMEN

    Oct 1, 2009, 00:00

  • PSY8 TAPENTADOL EXTENDED RELEASE (ER) FOR CHRONIC LOW BACK PAIN- RESULTS OF EUROQOL-5 DIMENSION (EQ-5D) AND SHORT FORM-36 (SF-36) HEALTH STATUS QUESTIONNAIRES

    Oct 1, 2009, 00:00

  • PDB20 A COST CONSEQUENCE MODEL TO ASSESS THE ECONOMIC IMPACT IN GERMANY OF PATIENTS ACHIEVING KDOQITM TARGETS WITH THE USE OF A COMBINATION OF CINACALCET + TRADITIONAL THERAPY (TT) COMPARED WITH TT ALONE

    Oct 1, 2009, 00:00

  • PIN37 COST EFFECTIVENESS OF PEGYLATED-INTERFERON ALPHA 2B + RIBAVIRIN FOR CHRONIC HEPATIITIS C (CHC) IN PATIENTS WHO HAVE PREVIOUSLY FAILED TREATMENT WITH INTERFERON- BASED THERAPY IN AUSTRALIA

    Oct 1, 2009, 00:00

  • PMH46 ESTIMATING THE COSTS OF PSYCHIATRIC HOSPITAL SERVICES IN NIGERIA; A CASE STUDY OF FEDERAL NEUROPSYCHIATRIC HOSPITAL ENUGU, SOUTH EAST NIGERIA

    Oct 1, 2009, 00:00

  • PCN79 COST-EFFECTIVENESS EVALUATION OF THE USE OF CAPECITABINE+DOCETAXEL VS GEMCITABINE+DOCETAXEL IN PATIENTS WITH RECURRENT BREAST CANCER WHO PREVIOUSLY FAILED TO ANTHRACYCLINE CHEMOTHERAPY AND/OR WITH METASTATIC DISEASE

    Oct 1, 2009, 00:00

  • PSY29 PHARMACOECONOMIC EVALUATION OF TREATMENT ANEMIA WITH ERYTHROPOIETIC AGENTS IN CHRONIC KIDNEY DISEASE PATIENTS

    Oct 1, 2009, 00:00

  • PHP62 FREE BUT VALUABLE- THE ECONOMIC SIGNIFICANCE OF SERVICES PROVIDED BY PORTUGUESE PHARMACIES

    Oct 1, 2009, 00:00

  • PND30 MEDICATION ADHERENCE WITH DISEASE MODIFYING TREATMENTS FOR MULTIPLE SCLEROSIS- FINDINGS FROM A US NATIONAL DATABASE OF EMPLOYEES

    Oct 1, 2009, 00:00

  • PCV115 TIROFIBAN IS MORE COST-EFFICIENT THAN ABCIXIMAB IN ACHIEVING ST-SEGMENT RESOLUTION FOLLOWING ACUTE MYOCARDIAL INFARCTION

    Oct 1, 2009, 00:00

  • PMS93 GREEK NHS CAPACITY CONSTRAINTS REGARDING IV TREATMENT FOR RHEUMATOID ARTHRITIS PATIENTS

    Oct 1, 2009, 00:00

  • PIN13 ANN Y CONTROL DE LA EPIDEMIA

    Oct 1, 2009, 00:00

  • PMH26 A COMPARISON OF TREATMENT PATTERNS AND COSTS FOR SUBJECTS NEWLY TREATED WITH DONEPEZIL VERSUS THOSE NEWLY TREATED WITH GALANTAMINE OR RIVASTIGMINE

    Oct 1, 2009, 00:00

  • PMS57 COST-UTILITY ANALYSIS OF BALLOON KYPHOPLASTY FOR PATIENTS WITH OSTEOPOROTIC VERTEBRAL COMPRESSION FRACTURES IN JAPAN

    Oct 1, 2009, 00:00

  • PCV53 FINANCIAL IMPACT OF A NOVEL PREECLAMPSIA DIAGNOSTIC TEST VS. STANDARD CARE- A DECISION-ANALYTIC MODELING ANALYSIS FROM A UK HEALTH CARE PAYER PERSPECTIVE

    Oct 1, 2009, 00:00

  • PMS63 COMPARISON OF STAFF RESOURCES AND PATIENT TIME REQUIRED FOR RITUXIMAB AND INFLIXIMAB ADMINISTRATION IN 3 UK NHS HOSPITALS

    Oct 1, 2009, 00:00

  • PSS20 ECONOMIC EVALUATION OF BIOLOGIC THERAPIES FOR MODERATE TO SEVERE PSORIASIS- ETANERCEPT COMPARED TO ADALIMUMAB AND INFLIXIMAB

    Oct 1, 2009, 00:00

  • PIH3 DUTASTERIDE PLUS TAMSULOSIN PROVIDES SUPERIOR IMPROVEMENTS IN PATIENT-REPORTED QUALITY OF LIFE- 4-YEAR RESULTS FROM THE COMBINATION OF AVODART AND TAMSULOSIN (COMBAT) STUDY

    Oct 1, 2009, 00:00

  • PCV147 EXPERIENCE WITH UPPER GASTROINTESTINAL SYMPTOMS IN PATIENTS WITH CARDIOVASCULAR RISK TREATED WITH LOW-DOSE ACETYLSALICYLIC ACID

    Oct 1, 2009, 00:00

  • PIN54 THE COST-EFFECTIVENESS OF THE NEW PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE (PCVI3) FOR CHILDHOOD AND ADULT VACCINATION IN THE UK

    Oct 1, 2009, 00:00

  • PCV127 EFFECT OF TOLVAPTAN ON HOSPITAL LENGTH OF STAY (LOS) WITHIN HYPONATREMIC PATIENTS HOSPITALIZED FOR HEART FAILURE

    Oct 1, 2009, 00:00

  • PRS31 PRESCRIPTION PATTERNS OF AND TREATMENT ADHERENCE TO INHALED CORTICOSTEROIDS AND LEUKOTRIENE-RECEPTOR ANTAGONISTS AMONG ASTHMATIC CHILDREN

    Oct 1, 2009, 00:00

  • PMC18 ANALYSIS OF TRANSFERABILITY TOOLS FOR COST-EFFECTIVENESS DATA AND COSIDERATION IN KOREA SETTINGS

    Oct 1, 2009, 00:00

  • PMC74 WHICH HEALTH ECONOMIC APPROACHES FOR WHICH DECISION-MAKING SUPPORT IN METASTATIC CANCER ? A LITERATURE REVIEW AND FRENCH EXPERT OPINIONS

    Oct 1, 2009, 00:00

  • PIN79 SYSTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF PALIVIZUMAB IN HIGH-RISK PATIENTS

    Oct 1, 2009, 00:00

  • PHP86 ADHERENCE OF PHARMACOECONOMIC STUDIES SUBMITTED FOR THE REIMBURSEMENT AND PRICING SYSTEM IN 2008 TO THE CZECH PHARMACOECONOMIC GUIDELINES

    Oct 1, 2009, 00:00

  • PCV43 USING ELECTRONIC MEDICAL RECORDS (EMRS) TO ASSESS ANTICOAGULATION STATUS ACCORDING TO STROKE RISK IN PATIENTS WITH ATRIAL FIBRILLATION IN AMBULATORY CARE SETTINGS

    Oct 1, 2009, 00:00

  • PR3 FIBROMYALGIA FATIGUE-DEVELOPMENT OF A CONCEPTUAL MODEL BASED ON QUALITATIVE PATIENT INTERVIEWS

    Oct 1, 2009, 00:00

  • PCV82 THE IMPACT OF LOST THERAPEUTIC BENEFIT (LTB) IN HIGH RISK PATIENTS MANAGED FOR HYPERTENSION IN AUSTRALIAN GENERAL PRACTICE

    Oct 1, 2009, 00:00

  • PHP10 QUALITY ASSURANCE OF FOURTH HURDLE IN HUNGARY- A METHODOLOGICAL APPROACH

    Oct 1, 2009, 00:00

  • PHP24 EXPERIDE

    Oct 1, 2009, 00:00

  • PHP17 DECENTRALIZATION AND ORGANIZATIONAL REFORM IN IRANIAN PUBLIC HOSPITALS AFFILIATED WITH MINISTRY OF HEALTH

    Oct 1, 2009, 00:00

  • PMH72 BENZODIAZEPINE USE AMONG FREQUENT ATTENDERS TO EMERGENCY DEPARTMENTS- A NATIONWIDE STUDY IN TAIWAN

    Oct 1, 2009, 00:00

  • PCV99 PHARMACOECONOMICS OF DIRECT RENIN INGIBITOR ALISKIREN IN HYPERTENSION TREATMENT OF PATIENTS WITH TYPE-2 DIABETES AND NEPHROPATHY

    Oct 1, 2009, 00:00

  • PND2 A BAYESIAN META-ANALYSIS COMPARING TREATMENTS FOR ALZHEIMERS DISEASE

    Oct 1, 2009, 00:00

  • PND20 REVERSAL OF NEUROMUSCULAR BLOCKADE WITH SUGAMMADEX- COST-EFFECTIVENESS ANALYSIS

    Oct 1, 2009, 00:00

  • PRS47 SEASONAL VERSUS NEEDS-BASED IMMUNIZATION SCHEDULES- THE EXAMPLE OF RSV

    Oct 1, 2009, 00:00

  • PIH28 VALIDATION OF THE SF-36 IN PATIENTS WITH ENDOMETRIOSIS

    Oct 1, 2009, 00:00

  • PMH3 FACTORS THAT PREDICT EARLY TREATMENT FAILURE AMONG PATIENTS IN OUTPATIENT TREATMENT FOR OPIOID DEPENDENCE

    Oct 1, 2009, 00:00

  • PCV157 MEDICATION ADHERENCE AND PERSISTENCE OF CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS WITH AND WITHOUT DIABETES MELLITUS

    Oct 1, 2009, 00:00

  • PHP2 DISTORNIA

    Oct 1, 2009, 00:00

  • PMC56 PREFERENCES FOR PREFERENCES

    Oct 1, 2009, 00:00

  • PHP2 PREDICTING PERSISTENT FREQUENT USE OF THE PRIMARY HEALTH CARE SERVICES IN A FINNISH SETTING- A BAYESIAN APPROACH

    Oct 1, 2009, 00:00

  • PCN51 THE COSTS OF BREAST CANCER PRIOR TO AND FOLLOWING DIAGNOSIS

    Oct 1, 2009, 00:00

  • PIH24 CHANGING THE SURGICAL WOUND CLOSURE MANAGEMENT PATHWAY- TIME AND SUPPLIES WITH PRINEO* VS. STANDARD OF CARE FOR BREAST RECONSTRUCTION SURGERY

    Oct 1, 2009, 00:00

  • PRS27 MARKOV MODEL FOR HEALTH-ECONOMIC EVALUATIONS OF COPD IN GERMANY

    Oct 1, 2009, 00:00

  • PR3 EFFECT OF PREHOSPITALIZATION PERIOD AND TYPE OF PESTICIDES ON OUTCOMES IN ACUTE ORGANOPHOSPHORUS POISONING

    Oct 1, 2009, 00:00

  • PND43 ASSOCIATION OF HEALTH-RELATED QUALITY OF LIFE AND RELAPSE IN THE PREVIOUS YEAR AMONG MULTIPLE SCLEROSIS PATIENTS- BASELINE DATA FROM ROBUST

    Oct 1, 2009, 00:00

  • PND1 RELATIONSHIP BETWEEN ADHERENCE TO INTERFERONS TO TREAT MULTIPLE SCLEROSIS AND THE NUMBER AND SEVERITY OF RELAPSES

    Oct 1, 2009, 00:00

  • PIN2 INTEGRATION OF PHARMACO-ECONOMIC OUTCOME BASED RESEARCH WITH LOCAL CONTEXT- A MODEL FOR RATIONAL HEALTH CARE DECISION-MAKING IN DEVELOPING COUNTRIES

    Oct 1, 2009, 00:00

  • PMH1 META-ANALYSIS OF CLINICAL OUTCOMES FROM GUIDELINE-RECOMMENDED PHARMACOTHERAPIES FOR GENERALIZED ANXIETY DISORDER (GAD)

    Oct 1, 2009, 00:00

  • PMS46 INDIRECT COSTS OF RHEUMATOID ARTHRITIS BEFORE AND AFTER 6 MONTHS OF TREATMENT WITH BIOLOGICS- THE GISEA STUDY

    Oct 1, 2009, 00:00

  • CASE2 REVIEW OF THE EARLY EXPERIENCE OF THE NEW NICE SCIENTIFIC ADVICE PROGRAMME

    Oct 1, 2009, 00:00

  • PDB38 COST SAVINGS IN TYPE 2 DIABETES WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN A BASAL SUPPORTED ORAL THERAPY (BOT) IN GERMANY

    Oct 1, 2009, 00:00

  • PMH3 OVERCOMING THE CHALLENGES OF MODELLING SCHIZOPHRENIA- A UK CASE STUDY OF THE COST-EFFECTIVENESS OF OLANZAPINE LONG-ACTING INJECTION VS. RISPERIDONE LONG-ACTING INJECTION

    Oct 1, 2009, 00:00

  • PHP25 IMPACT OF REDUCED COPAYMENTS ON MEDICATION ADHERENCE- DX-RX PAIRINGTM PROGRAM OUTCOMES

    Oct 1, 2009, 00:00

  • PHP23 PROPUESTA PARA EL ESTABLECIMIENTO DE UN MODELO DE LA EVALUACIA

    Oct 1, 2009, 00:00

  • PG19 COST-EFFECTIVENESS OF INTRAVENOUS IRON IN INFLAMMATORY BOWEL DISEASE PATIENTS INTOLERANT TO ORAL IRON

    Oct 1, 2009, 00:00

  • PIN9 THE COST OF PREVENTING INFLUENZA PANDEMIC- MEXICAN ELDERLY POPULATION SCENARIO

    Oct 1, 2009, 00:00

  • UT1 VALUING EQ-5D USING TIME TRADE-OFF IN FRANCE

    Oct 1, 2009, 00:00

  • PIH1 PERCEPTION OF PAIN AFTER CAESAREAN SECTION FROM THE POINT OF VIEW OF PUERPERAL MOTHERS

    Oct 1, 2009, 00:00

  • PCV95 COST-EFFECTIVENESS OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES IN SOUTH KOREA

    Oct 1, 2009, 00:00

  • PDB45 ASSESSING UTILITIES AND DISUTILITIES FOR TYPE 2 DIABETES TREATMENT-RELATED ATTRIBUTES IN AN ASIAN POPULATION

    Oct 1, 2009, 00:00

  • PDB50 THE COST OF DIABETES RELATED MINOR HYPOGLYCEMIC EVENTS IN WORKING ADULTS

    Oct 1, 2009, 00:00

  • PCV63 COST OF CARDIOVASCULAR DISEASE IN KOREA- INCIDENCE-BASED APPROACH

    Oct 1, 2009, 00:00

  • PSS12 THE ECONOMIC IMPACTS OF ACUTE OTITIS MEDIA IN TAIWAN

    Oct 1, 2009, 00:00

  • PCN62 COST ANALYSIS OF HORMONE RECEPTOR POSITIVE, ADVANCED BREAST CANCER TREATMENT WITH ENDOCRINE THERAPY VERSUS CHEMOTHERAPY IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM (BPHS)

    Oct 1, 2009, 00:00

  • PIN58 COST-EFFECTIVENESS OF ETRAVIRINE IN SWEDEN IN TREATMENT-EXPERIENCED HIV-I-INFECTED ADULTS WITH EVIDENCE OF NNRTI RESISTANCE AND AT LEAST 3 PI MUTATIONS

    Oct 1, 2009, 00:00

  • PIN2 HCV INFECTION IS ASSOCIATED WITH HIGH COMORBIDITY BURDEN IN EUROPE

    Oct 1, 2009, 00:00

  • PR1 A LATENT GENERAL GROWTH MIXTURE MODEL FOR HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH PARKINSON DISEASE ACROSS 36 MONTH

    Oct 1, 2009, 00:00

  • PMS97 FACTORS INFLUENCING REIMBURSEMENT AND PRESCRIPTION DECISIONS ON THE RHEUMATOID ARTHRITIS MAKET IN GERMANY, SPAIN, ITALY, FRANCE AND UK

    Oct 1, 2009, 00:00

  • PND32 NEW QUALITY OF LIFE (QOL) DATA ON UK PATIENTS WITH REFRACTORY NEUROPATHIC PAIN

    Oct 1, 2009, 00:00

  • PCV65 TWO-YEAR CLINICAL AND ECONOMIC IMPACT OF PERIPHERAL ARTERIAL DISEASE ON PATIENTS FROM SPAIN WITH ESTABLISHED CORONARY ARTERY OR CEREBROVASCULAR DISEASE- RESULTS FROM THE REDUCTION OF ATHEROTHROMBOSIS FOR CONTINUED HEALTH (REACH) REGIS ...

    Oct 1, 2009, 00:00

  • PDB13 ENCUESTA SOBRE LAS PRACTICAS DE UTILIZACION Y TITULACION DE INSULINA EN LATINOAMERICA

    Oct 1, 2009, 00:00

  • PCV106 PREDICTED COST-EFFECTIVENESS OF ACHIEVING MULTIPLE OPTIMAL LIPID VALUES WHEN FENOFIBRIC ACID IS CO-ADMINISTERED WITH A STATIN IN SPECIAL PATIENT POPULATIONS WITH MIXED DYSLIPIDEMIA

    Oct 1, 2009, 00:00

  • PIH21 COST-EFFECTIVENESS OF PAEDIATRIC PNEUMOCOCCAL VACCINATION IN THE NETHERLANDS; AN UPDATE FOR THE 7-VALENT AND FORECAST FOR THE 10-AND 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINES (PCVS)

    Oct 1, 2009, 00:00

  • PIH6 CHANGES OF HEART RATE VARIABILITY AFTER SHORT-TERM MEDITATION TRAINING IN COLLEGE STUDENT

    Oct 1, 2009, 00:00

  • PMH66 QUALITY OF LIFE AND PATIENT-REPORTED OUTCOMES- COMPARISONS OF INDIVIDUALS WITH SCHIZOPHRENIA TREATED WITH ORAL AND LONG-ACTING INJECTABLE FORMULATIONS OF OLANZAPINE

    Oct 1, 2009, 00:00

  • PIH30 SYMPTOMS AND IMPACT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD)- CONCEPTS AND MEASUREMENT

    Oct 1, 2009, 00:00

  • PIH38 RELATIONSHIP BETWEEN HEALTH-RELATED QUALITY OF LIFE AND MULTIMORBIDITY AMONG OLDER PERSONS IN GERMANY-RESULTS OF THE PRISCUS-COHORT

    Oct 1, 2009, 00:00

  • PCV27 COUNTRY-SPECIFIC DIFFERENCES IN 12-MONTH PATTERNS OF ANTIPLATELET USE IN ACS PATIENTS UNDERGOING PCI IN 2007-08- RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY (APTOR)

    Oct 1, 2009, 00:00

  • PG16 EVALUATION OF RESOURCE UTILIZATION AND ECONOMIC IMPACT OF RECURRENCE FOR INGUINAL HERNIA REPAIR PERFORMED WITH PHS DEVICE VERSUS POLYPROPYLENE MESH UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE

    Oct 1, 2009, 00:00
  • «
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150 (current)
  • »